nav-left cat-right
cat-right

ADC SUMMIT 19TH & 20TH MAY 2014

Venue: Holiday Inn Regents Park Hotel, London, United Kingdom Antibody Drug Conjugates (ADCs) offer the promise and potential of delivering powerful tumour-killing activity with the advantage of reduced side effects for cancer patients. While one of the biggest challenges in manufacturing these powerful ADCs is controlling all the components that go into the final conjugation step, researchers do believe that further...

Key indicator of heart diseases

A team that includes Dartmouth College researchers has discovered a new way to detect cardiolipin, a key indicator of heart diseases and some genetic disorders. The results, which appear in the journal Analytical Chemistry, may eventually help to diagnose these conditions earlier on and to provide real-time monitoring of cardiolipin levels. Cardiolipin is a unique lipid of mitochondria, the cell structures that generate...

The NCI is offering $20M to projects that move can...

The National Cancer Institute (NCI) faces a growing data problem. As the scale of its projects grows–one initiative is expected to generate 2.5 petabytes of data–downloading results for analysis on local systems becomes impractical. Recognizing this, the NCI has allocated $20 million for cloud-based genomics pilot projects. Having spent last year gathering feedback on what users want from cloud-based cancer...

Body kills ‘spontaneous’ blood cancers...

Immune cells undergo ‘spontaneous’ changes on a daily basis that could lead to cancers if not for the diligent surveillance of our immune system, Melbourne scientists have found. The research team from the Walter and Eliza Hall Institute found that the immune system was responsible for eliminating potentially cancerous immune B cells in their early stages, before they developed into B-cell lymphomas (also known as...

Immunocore and GlaxoSmithKline team to work on imm...

Immunocore’s list of collaborators is beginning to look like a Who’s Who in Big Pharma. Today the biotech–which is developing T cell immunotherapy technology originally spun out of Oxford–added a deal-hungry AstraZeneca ($AZN) and its biologics team at MedImmune as its latest partner, which will now join Genentech and GlaxoSmithKline in exploring whether the biotech has really found a powerful new...

UC Santa Cruz Wins DREAM Breast Cancer Challenge

November 8, 2013 | A team of bioinformatics experts at UC Santa Cruz made the most accurate predictions in a competitive challenge to identify signaling networks in breast cancer cells. The results of the HPN-DREAM breast cancer network inference challenge were announced today in Toronto. The breast cancer network inference challenge was organized by the DREAM project (Dialogue on Reverse Engineering Assessment and Methods),...
Page 5 of 28« First...34567...1020...Last »